Saturday, 14 February 2015: 10:00 AM-11:30 AM
Room 230C (San Jose Convention Center)
Numerous pharmaceutical approaches have focused on proteinopathic, neurophysiologic and immune-inflammatory targets in Alzheimer’s disease. The disadvantage of requiring cognitive-psychological –behavioral diagnosis before initiating therapy late in the course of disease pathogenesis has resulted in universal failure. The emerging capacities for preclinical identification of disease onset and separate delineation of individual disease processes now is expected to lead to successful therapies.